Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.61 |
| ▸ | NEK2 | P51955 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27708260 | 0.89 | MAP2K1 (0.71) | MAP2K1NEK2ADORA2ACAMKK2CCNE1 | |
| SCHEMBL12772764 | 0.88 | MAP2K1 (0.58) | MAP2K1NEK2ADORA2ACAMKK2CCNE1 | |
| SCHEMBL878925 | 0.88 | KIF20A (0.59) | MAP2K1NEK2ADORA2ACAMKK2CCNE1 | |
| SCHEMBL2984625 | 0.87 | MAP2K1 (0.61) | MAP2K1NEK2ADORA2ACAMKK2CNR2 | |
| SCHEMBL29468201 | 0.85 | MAP2K1 (0.71) | MAP2K1ADORA2ACAMKK2METCCNE1 | |
| SCHEMBL985214 | 0.85 | MAP2K1 (0.71) | MAP2K1ADORA2ACAMKK2METCCNE1 | |
| SCHEMBL8387910 | 0.84 | MAP2K1 (0.55) | MAP2K1NEK2ADORA2ACAMKK2MET | |
| SCHEMBL857000 | 0.84 | NEK2 (0.58) | MAP2K1NEK2ADORA2ACAMKK2CCNE1 | |
| SCHEMBL411058 | 0.84 | NEK2 (0.53) | MAP2K1NEK2KDRKMT2AROCK1 | |
| Hydrochloric Acid SCHEMBL3608101 | 0.83 | MAP2K1 (0.69) | MAP2K1ADORA2ACAMKK2METCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559489-B2 | Antagonistic small molecule compound having toll-like receptor 7/9 inhibitory function | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-24 | — | — | US | claimed |
| US-7872016-B2 | Method for treating skeletal disorders resulting from FGFR malfunction | YALE UNIVERSITY (US) | 2011-01-18 | — | — | US | claimed |
| EP-1773305-A2 | METHOD FOR TREATING SKELETAL DISORDERS RESULTING FROM FGFR MALFUNCTION | Yale University Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | claimed |
| WO-2005115363-A9 | METHOD FOR TREATING SKELETAL DISORDERS RESULTING FROM FGFR MALFUNCTION | UNIV YALE (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2005115363-A2 | METHOD FOR TREATING SKELETAL DISORDERS RESULTING FROM FGFR MALFUNCTION | YALE UNIVERSITY (US) | 2005-12-08 | — | — | WO | claimed |
| CN-114981267-B | 3-Benzoyl-1H-pyrrolo [2,3-B ] pyridine derivatives as MKK4 inhibitors for the treatment of liver diseases | 海帕瑞吉尼克斯股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114981267-B | 3-Benzoyl-1H-pyrrolo [2,3-B ] pyridine derivatives as MKK4 inhibitors for the treatment of liver diseases | 海帕瑞吉尼克斯股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4090659-C0 | 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES | HEPAREGENIX GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| EP-4090659-B1 | 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES | HEPAREGENIX GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-20230339935-A1 | ANTAGONISTIC SMALL MOLECULE COMPOUND HAVING TOLL-LIKE RECEPTOR 7/9 INHIBITORY FUNCTION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-26 | — | — | US | disclosed |
| US-20230339935-A1 | ANTAGONISTIC SMALL MOLECULE COMPOUND HAVING TOLL-LIKE RECEPTOR 7/9 INHIBITORY FUNCTION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-26 | — | — | US | disclosed |
| US-20230088395-A1 | 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES | HEPAREGENIX GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1696920-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005115363-A9 | METHOD FOR TREATING SKELETAL DISORDERS RESULTING FROM FGFR MALFUNCTION | UNIV YALE (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005115363-A2 | METHOD FOR TREATING SKELETAL DISORDERS RESULTING FROM FGFR MALFUNCTION | YALE UNIVERSITY (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | MAP2K1 2201/4885NEK2 1496/4885ADORA2A 3358/4885 |
| US-12559489-B2 | Antagonistic small molecule compound having toll-like receptor 7/9 inhibitory function | TLR9, TLR7, TLR1 | MAP2K1 69/4885NEK2 2148/4885ADORA2A 2158/4885 |
| US-20230339935-A1 | ANTAGONISTIC SMALL MOLECULE COMPOUND HAVING TOLL-LIKE RECEPTOR 7/9 INHIBITORY FUNCTION | TLR9, TLR7, TLR1 | MAP2K1 569/4885NEK2 2828/4885ADORA2A 2010/4885 |
| US-20230088395-A1 | 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES | NR1H4, MAPK4, NR1H2 | MAP2K1 71/4885NEK2 1115/4885ADORA2A 4043/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | MAP2K1 3057/4885NEK2 1178/4885ADORA2A 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.